HERMS white paper
Discover the HERMS life sciences platform and our regulatory affairs expertise.
Download the editable Word white paper
HERMS WHITE PAPER | WP2 | NOVEMBER 2026
GCC Market Access Playbook
Registration, Pricing and Tender Sequencing
In the GCC, a registration certificate is only the first of four gates. This playbook shows how to sequence registration, pricing, reimbursement and tenders across six markets so that a new medicine reaches patients faster and at a sustainable price.
HERMS Consultancy DMCC
Dubai, United Arab Emirates | info@hermsglobal.com | www.hermsglobal.com
Contents
Executive Summary
1. Why Sequencing Decides Success
2. The GCC Access Landscape
3. Gate 1: Registration
4. Gate 2: Pricing
5. Gate 3: Reimbursement and Formulary
6. Gate 4: Tenders and Procurement
7. Launch Sequencing Strategies
8. The HERMS 24-Month Access Roadmap
9. Pitfalls and Readiness Checklist
10. How HERMS Helps
References
Executive Summary
The six GCC states share a Gulf Health Council framework but run their own regulators, pricing committees, formularies and purchasing bodies. Most delays and value losses happen when companies treat these as separate projects run one after another. Market access in the GCC is a sequencing problem: the order and timing of decisions across registration, pricing, reimbursement and tenders determine both speed and price.
| 30 / 60 working-day SFDA targets for verification and abridged reliance review1 | 2 years window after reference approval to use SFDA reliance pathways1 | July 2025 economic evaluation dossiers mandatory for key product types in Saudi Arabia9 | SAR 2.4bn+ Gulf joint procurement tenders conducted in 20254 |
Five principles of the playbook
- Plan all four gates from day one. Registration, pricing, reimbursement and tender readiness should be prepared in parallel, not in sequence.
- Protect the price corridor. Several GCC states reference each other's prices, often taking the lowest.6 The first GCC price set can cap prices across the region.
- Use reliance early. SFDA reliance pathways must be used within two years of reference-agency approval.1 Late filers lose the fastest route.
- Build value evidence before launch. Saudi Arabia now requires economic evaluation for new, high-cost and first-in-class products, and Abu Dhabi has published HTA guidelines.9,13
- Work back from the tender calendar. Registration, pricing, listing and supplier qualification must all be complete before the bid deadline.16
| HERMS view The fastest GCC launches are not those with the fastest single approval. They are those in which every gate is ready when the previous one opens. |
1. Why Sequencing Decides Success
A new medicine passes through four gates before it reaches patients through the public sector in the GCC:
| Gate | Decision | Main decision-makers |
| 1. Registration | Is the product safe, effective and of good quality? | SFDA, EDE, national authorities, Gulf Health Council |
| 2. Pricing | What is the maximum price? | National pricing committees |
| 3. Reimbursement and formulary | Will payers and hospitals use and pay for it? | Ministries of health, insurers, hospital P&T committees |
| 4. Tender and procurement | Who supplies what volume, at what price? | NUPCO, Gulf Health Council, national and emirate buyers |
How sequencing errors cost time and value
- Lost reliance window: filing in Saudi Arabia more than two years after FDA or EMA approval removes eligibility for verification and abridged review.1
- Price cascade: a low price agreed in one GCC state can be referenced by others using lowest-price rules.6
- Missed tender: a product registered but not priced, listed or supplier-qualified at the bid deadline waits for the next cycle.16
- Evidence gap: a missing economic evaluation dossier can stall pricing or listing in Saudi Arabia.9
The result is visible in availability data: of 460 new medicines launched globally in 2012–2021, 38% reached Saudi Arabia, 33% the UAE and 14% Kuwait, with average delays of 27–32 months after first global launch.21
2. The GCC Access Landscape
The table summarises the main bodies and pricing approaches. Pricing methods are drawn from published rules and a 2018 regional mapping and should be confirmed with each authority before use.
| Market | Regulator | Pricing approach | HTA and value evidence | Main public purchasing |
| Saudi Arabia | SFDA | Pricing Rules weigh added therapeutic value, alternatives, economic studies and prices in a 16-country reference list5 | Economic evaluation mandatory for key product types since July 2025; SFDA and CCHI9 | NUPCO unified procurement17 |
| UAE | EDE (federal); DoH Abu Dhabi and DHA at emirate level | External reference pricing using Gulf and European prices7; 2018 mapping: median of 18 countries6 | DoH Abu Dhabi HTA guidelines published 2025; Dubai HTA pilot 2025–2713 | Federal and emirate-level purchasing, including Abu Dhabi Unified Purchasing Program14 |
| Kuwait | Ministry of Health | 2018 mapping: lowest GCC price and an average across a wider basket6 | No national HTA body identified in sources reviewed | MOH procurement; GHC joint procurement |
| Qatar | Ministry of Public Health | 2018 mapping: lowest price; country of origin and GCC basket6 | National HTA unit project launched January 202515 | National purchasing; GHC joint procurement |
| Bahrain | NHRA | 2018 mapping: lowest price; GCC states and country of origin6 | No national HTA body identified in sources reviewed | National purchasing; GHC joint procurement |
| Oman | Ministry of Health | 2018 mapping: lowest price; GCC states and country of origin6 | No national HTA body identified in sources reviewed | National purchasing; GHC joint procurement |
The regional layer
- Gulf Health Council central registration offers consolidated registration across member states. Its programme had reached 2,021 registered pharmaceutical products by 2025.4
- Gulf Joint Procurement Program runs scheduled tenders for member states and conducted tenders exceeding SAR 2.4 billion in 2025.4,18
3. Gate 1: Registration
Choose the route
| Route | Best suited to | Key requirements |
| SFDA verification | Products approved by both FDA and EMA | Filed within two years of reference approval; manufacturer in an eligible country; 30 working-day target1 |
| SFDA abridged | Products approved by one reference authority | Same eligibility conditions; 60 working-day target1 |
| UAE marketing authorisation (EDE) | UAE entry | 45 working-day stated service duration2 |
| Gulf Health Council central registration | Multi-country portfolios from manufacturers with GHC-registered companies and sites | Company registration with GMP inspection; response to inspection report within 90 days; national administrative completion within six months3 |
| National standard review | Products without eligible reference approvals | Full assessment; longest timelines |
Registration readiness
- Legalised certificates (CPP, GMP, manufacturing licence) ready before submission.
- Dossier aligned to the reference-agency approved version for reliance routes.1
- Arabic labelling and patient leaflet prepared in parallel.
- Lifecycle plan: SFDA requires the same reference agency to be used for variations.1
- Pricing documents prepared for submission alongside registration (see Gate 2).
4. Gate 2: Pricing
Saudi Arabia
The SFDA Pricing Rules state that a product is priced taking into account its added therapeutic value, the prices of registered therapeutic alternatives, economic evaluation studies, ex-factory and wholesale prices in the country of origin, export prices to markets where it is sold, and prices in approved reference sources. The price certificate must not be more than six months old at the time of pricing.5
- The approved price is a maximum; the company may sell lower.5
- Generic ceilings: first generic 70%, second 65%, third and later 60% of the originator price before generic entry.5
- The price certificate lists 16 reference countries, including Australia, Canada, France, Germany, Japan, South Korea and the UK.5
United Arab Emirates
- EDE pricing certificate applications require the proposed UAE price and CIF prices in reference countries where the product is marketed.7
- Re-pricing applications require reference prices from Gulf and European countries.8
Price referencing across the GCC
A 2018 regional mapping found that Bahrain, Oman and Qatar applied lowest-price rules with GCC states in their baskets, while the UAE used a median price across 18 countries.6 Kuwait's Ministry of Health has reduced prices for hundreds of products to be the lowest in the GCC.20 Because states reference each other, the first GCC price is a regional decision.
| Price corridor rules 1. Agree a single GCC target price corridor before the first submission. 2. Do not accept a price in one state that falls below the corridor floor without modelling the regional impact. 3. Submit pricing applications in an order that sets reference prices in the most-referenced markets first. 4. Keep confidential discounts, rebates and managed entry agreements separate from list prices where permitted. |
5. Gate 3: Reimbursement and Formulary
Saudi Arabia
- From July 2025, economic evaluation dossiers are mandatory for new drugs and biologics, orphan drugs, high-cost or re-priced drugs, and first-in-class drugs or biosimilars for high-impact diseases.9
- SFDA conducts the assessment and its findings, including cost-effectiveness and budget impact, inform pricing. CCHI determines insurance coverage and MOH lists products for public use.9
- SFDA has published Economic Evaluation Studies Guidelines that apply to registration, price re-evaluation and renewal.10
- MOH formulary additions must be requested by a consultant or senior registrar and approved through hospital and regional committees.12
- The MOH Managed Entry Agreement Policy covers financial agreements (discounts, price-volume, paybacks, free doses, dose caps) and value-based agreements linked to outcomes, involving MOH, NUPCO, manufacturers and providers.11
United Arab Emirates
- DoH Abu Dhabi launched an HTA unit in 2018 and published HTA guidelines for high-cost therapies and devices in 2025.13
- DoH Abu Dhabi has added coverage indicators, including a definition for performance-based managed entry agreements, to its drug coding list.14
- Outside Abu Dhabi, HTA activity remains limited; Dubai is piloting a technology-driven HTA system in 2025–27.13
Value dossier essentials
| Component | Content |
| Clinical value | Comparative efficacy and safety against local standard of care |
| Economic evaluation | Cost-effectiveness model adapted to local costs and practice, following SFDA guidelines where applicable10 |
| Budget impact | Eligible population, uptake and net budget effect over three to five years |
| Local epidemiology | Prevalence and disease burden in the target market |
| Managed entry proposal | Financial or outcomes-based agreement options11 |
6. Gate 4: Tenders and Procurement
Saudi Arabia: NUPCO
- NUPCO runs unified procurement for government health sectors.17
- Suppliers must be registered and qualified with NUPCO before buying the tender booklet through SADAD.16
- Initial results usually follow technical and financial evaluation within 4–8 weeks, and objections are answered within a further 4–8 weeks.16
- Some published NUPCO tender announcements specify three-year contract periods.22
- Saudi Arabia has applied an additional price preference for national products in pharmaceutical and medical sectors since 2020.19
Regional: Gulf Joint Procurement
- The Gulf Health Council publishes an annual tender schedule and procures medicines, vaccines, supplies and devices for member states through joint committees.18,4
Tender readiness timeline
| Months before bid deadline | Requirement |
| 12+ | Registration submitted in target markets; tender calendar mapped |
| 9 | Pricing application submitted; supplier registration and qualification started |
| 6 | Price approved; formulary or catalogue listing requested |
| 3 | Technical documents, certificates and samples prepared; tender price modelled |
| 1 | Bid bond, compliance check item by item, final pricing approval |
7. Launch Sequencing Strategies
There is no single correct sequence. The right choice depends on product type, evidence, price position and supply capacity.
| Strategy | When to use it | Advantages | Watch-outs |
| Saudi-first | Products eligible for SFDA reliance with strong value evidence | Largest market; NUPCO volume; reliance targets of 30–60 working days1 | Mandatory economic evaluation for key product types9; price becomes a regional reference |
| UAE-first | Products seeking early private-market access and visibility | 45 working-day stated EDE service duration2; private insurance channel | Emirate-level formulary and HTA steps; median-based referencing6 |
| Parallel Saudi and UAE | Innovative products with complete dossiers and a set price corridor | Shortest overall time to patient | Requires strong local teams and coordinated pricing |
| GHC central route | Portfolios from manufacturers with GHC-registered companies and sites | One process for several states; access to joint procurement3,4 | Company and GMP registration first; national administrative steps still needed |
| Typical HERMS recommendation for an innovative medicine File Saudi Arabia and the UAE in parallel within months of the first reference approval, set a GCC price corridor before either pricing decision, prepare a Saudi economic evaluation and an Abu Dhabi value dossier during registration, and follow with Kuwait, Qatar, Bahrain and Oman once reference prices are established. |
8. The HERMS 24-Month Access Roadmap
Month 0 is the first FDA or EMA approval. Activities in the same column run in parallel.
| Workstream | Months −6 to 0 | Months 0 to 6 | Months 6 to 12 | Months 12 to 24 |
| Registration | Dossier, legalisation, Arabic labelling, route selection | Saudi and UAE submissions under reliance where eligible | Approvals; Kuwait, Qatar, Bahrain, Oman submissions | Remaining approvals; variations |
| Pricing | GCC price corridor and referencing model | Saudi and UAE pricing applications | Saudi and UAE prices approved | Other GCC prices within corridor |
| Value and reimbursement | Local economic model and budget impact | Saudi economic evaluation dossier; Abu Dhabi value dossier | Formulary and coverage decisions; managed entry agreement negotiation | Formulary listings across GCC |
| Tenders | Tender calendar map; supplier qualification | NUPCO and GHC qualification complete | First tender submissions | Awards; supply contracts |
| Launch operations | Local agent, distributor and pharmacovigilance set-up | Import permits, stock planning | First supply | Market expansion |
Timelines are indicative and depend on product type, authority workload and evidence requirements.
9. Pitfalls and Readiness Checklist
Ten common pitfalls
- Filing in Saudi Arabia after the two-year reliance window has closed.1
- Accepting a low price in a small market that is referenced by others.6
- Price certificates more than six months old at the time of Saudi pricing.5
- No economic evaluation dossier for a product type that requires one in Saudi Arabia.9
- Registering a product but not qualifying as a supplier before the tender opens.16
- Tender item descriptions that do not match the buyer's catalogue.
- Arabic labelling finalised after registration approval.
- Treating each emirate in the UAE as identical for formulary and coverage.
- No managed entry proposal for a high-cost product.11
- Separate country teams with no single owner of the GCC timeline.
Readiness checklist
| Area | Ready when |
| Registration | Route chosen, dossier aligned, certificates legalised, Arabic labelling approved internally |
| Pricing | GCC price corridor approved, reference prices documented, certificates current |
| Value evidence | Local cost-effectiveness and budget-impact models complete |
| Reimbursement | Formulary sponsors identified; managed entry options defined |
| Tenders | Supplier qualification complete; tender calendar mapped; catalogue items matched |
| Operations | Local agent, distributor, QPPV and supply plan in place |
10. How HERMS Helps
HERMS Consultancy DMCC supports pharmaceutical, biotechnology and medical device companies across every gate of GCC market access.
- Access strategy: market prioritisation, launch sequencing and GCC price corridor modelling.
- Registration: route selection, dossier preparation, submission management, renewals and variations.
- Pricing and value: pricing applications, economic evaluation dossiers, budget-impact models and managed entry proposals.
- Tenders: supplier qualification, tender calendar planning, technical compliance and bid preparation.
- Launch operations: pharmacovigilance, Arabic labelling and promotional compliance.
| Request a GCC access sequencing review HERMS will map your product against all four gates in each GCC market and deliver a 24-month access roadmap. info@hermsglobal.com | +971 55 600 8944 | www.hermsglobal.com |
References
1. SFDA. Verification and Abridged Pathways, Version 3.0. https://www.sfda.gov.sa/sites/default/files/2025-10/VerificationAbridgedPathways3.pdf
2. Emirates Drug Establishment. Issuance of Marketing Authorization for a Drug or Biopharmaceutical Product. https://www.ede.gov.ae/en/w/issuance-of-marketing-authorization-for-a-drug-or-biopharmaceutical-product
3. Gulf Health Council. Bylaws for Registration of Pharmaceutical Companies and their Products. https://www.ghc.sa/wp-content/uploads/2026/09/BYLAWS-FOR-REGISTRATION-OF-PHARMACEUTICAL-COMPANIES-AND-THEIR-PRODUCTS.pdf
4. Gulf Health Council. Annual Report 2025. https://www.ghc.sa/wp-content/uploads/2026/05/Gulf-Health-Annual-Report-2025.pdf
5. SFDA. Pricing Rules for Pharmaceutical Products (effective 14 January 2021). https://oldsfda.sfda.gov.sa/sites/default/files/2022-10/PharmaceuticalPricingRulesE.pdf
6. LSE Consulting. Pharmaceutical pricing and reimbursement in the Middle East and North Africa region, November 2018. https://www.lse.ac.uk/business/consulting/assets/documents/p…
7. Emirates Drug Establishment. Issue of a Single Medical Product Pricing Certificate. https://www.ede.gov.ae/en/web/ede/w/issue-of-a-single-medical-product-pricing-certificate
8. Emirates Drug Establishment. Re-pricing of a Single Medical Product. https://www.ede.gov.ae/en/w/re-pricing-of-a-medicine
9. PharmaBoardroom. Market Access and Health Technology Assessment: Saudi Arabia. https://pharmaboardroom.com/legal-reports/market-access-health-technology-assesment-saudi-arabia/
10. SFDA. Economic Evaluation Studies Guidelines. https://www.sfda.gov.sa/sites/default/files/2026-08/EconomicEvaluationStudies_1.pdf
11. Saudi MOH. Managed Entry Agreement Policy. https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/Managed-Entry-Agreeement-Policy-MEA.pdf
12. Saudi MOH. Formulary New Addition Request Form. https://www.moh.gov.sa/PublishingImages/%D9%86%D9%85%D9%88%D…
13. Health technology assessment infrastructure for the Emirates (Frontiers / PMC), 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12588929/
14. Department of Health Abu Dhabi. Circular on Performance-Based Managed Entry Agreement indicators. https://www.doh.gov.ae/-/media/A0CFFFD01F9044C9978EFA7F9CC0AC59.ashx
15. Policy dialogue on health technology assessment in the Middle East and North Africa: an HTAi initiative (PMC). https://pmc.ncbi.nlm.nih.gov/articles/PMC13440439/
16. NUPCO. Tenders FAQs. https://www.nupco.com/en/tenders/tenders-faqs/
17. NUPCO. Unified Procurement. https://www.nupco.com/en/service/unified-procurement/
18. Gulf Health Council. Joint Procurement. https://www.ghc.sa/en/procurement/
19. Global Trade Alert. Saudi Arabia: additional price preference for national products, September 2020. https://globaltradealert.org/state-act/46563
20. Kuwait Times. MoH cuts prices of 517 medicines and pharmaceutical products. https://kuwaittimes.com/article/48806/kuwait/moh-cuts-prices-of-517-medicines-and-pharmaceutical-products/
21. PhRMA. Global Access to New Medicines Report, April 2023. https://cdn.aglty.io/phrma/global/blog/import/pdfs/2023-04-20-PhRMA-Global-Access-to-New-Medicines-Report-FINAL-1.pdf
22. NUPCO. Tender announcement NPT 0004/25. https://www.nupco.com/wp-content/uploads/2026/06/GPPRR-NPT0004-25-_WEBSITE-Tender-announcement-1.pdf
Disclaimer: This white paper is for information only and does not constitute legal, regulatory, pricing or financial advice. It reflects public sources available on 5 November 2026. Some pricing details come from a 2018 regional mapping and may have changed. Confirm current rules with each authority before acting. © 2026 HERMS Consultancy DMCC.
